Experiences with SCRAMx alcohol monitoring technology in 100 alcohol treatment outpatients
Experiences with SCRAMx alcohol monitoring technology in 100 alcohol treatment outpatients
复制标题
DOI：
10.1016/j.drugalcdep.2017.05.031
复制
发表时间：
2017-09-01
影响因子：
4.2
通讯作者：
Petry, Nancy M.
中科院分区：
文献类型：
--
作者：
Alessi, Sheila M.;Barnett, Nancy P.;Petry, Nancy M.
背景：经皮酒精监测技术允许对酒精使用障碍进行新的研究。本研究通过两项临床研究试验评估了该技术的可行性、可接受性和依从性。方法：参与者是首批100名社区酒精治疗门诊患者，他们参加了随机研究，使用安全连续远程酒精监测器（SCRAMx (R)）监测饮酒12周。研究1的参与者被随机分为常规治疗组（n = 36）和常规治疗组（CM-Att; n = 30）。研究2的参与者被随机分为常规治疗组（n = 17）或常规治疗组（CM- abst, n = 17），每天不饮酒。12周后，参与者完成了一份关于手镯的调查。结果：接受筛查的人中有9%（595人中有54人）因为手环而拒绝参与。在参与者中，84%提供了12周的数据，96%的手环完好无损地返回。发生94起设备篡改事件，影响监测天数的2%；56%（67）的篡改行为与检测到的饮酒相吻合。参与者报告的常见问题是皮肤印记（58%）、刺激（54%）和干扰服装选择（51%），但严重程度一般较轻（60%-94%）。81%的参与者报告说，手镯帮助他们减少了饮酒，75%的人表示他们会戴更长的时间。一个普遍的改进建议是减小手镯的尺寸。结论：结果支持在自愿药物滥用治疗参与者中进行长期透皮监测的可行性。讨论了该技术未来应用需要考虑的问题。
Background: Transdermal alcohol monitoring technology allows for new research on alcohol use disorders. This study assessed feasibility, acceptability, and adherence with this technology in the context of two clinical research trials.Methods: Participants were the first 100 community-based alcohol treatment outpatients enrolled in randomized studies that monitored drinking with the secure continuous remote alcohol monitor (SCRAMx (R)) for 12 weeks. Study 1 participants were randomized to usual care (n = 36) or usual care with contingency management incentives for treatment attendance (CM-Att; n = 30). Study 2 participants were randomized to usual care (n = 17) or usual care with CM for each day of no drinking per SCRAMx (CM-Abst; n = 17). After 12 weeks, participants completed a survey about the bracelet.Results: Nine percent of individuals screened (54 of 595) declined participation because of the bracelet. Of participants, 84% provided 12 weeks of data, and 96% of bracelets were returned fully intact. Ninety-four equipment tampers occurred, affecting 2% of monitoring days; 56% (67) of tampers coincided with detected drinking. Common concerns reported by participants were skin marks (58%), irritation (54%), and interfered with clothing choices (51%), but severity ratings were generally mild (60%-94%). Eighty-one percent of participants reported that the bracelet helped them reduce drinking, and 75% indicated that they would wear it for longer. A common suggestion for improvement was to reduce the size of the bracelet.Conclusions: Results support the viability of transdermal monitoring in voluntary substance abuse treatment participants for an extended duration. Issues to consider for future applications of this technology are discussed.